Literature DB >> 16515583

Predicting the clinical behavior of ovarian cancer from gene expression profiles.

F De Smet1, N L M M Pochet, K Engelen, T Van Gorp, P Van Hummelen, K Marchal, F Amant, D Timmerman, B L R De Moor, I B Vergote.   

Abstract

We investigated whether prognostic information is reflected in the expression patterns of ovarian carcinoma samples. RNA obtained from seven FIGO stage I without recurrence, seven platin-sensitive advanced-stage (III or IV), and six platin-resistant advanced-stage ovarian tumors was hybridized on a complementary DNA microarray with 21,372 spotted clones. The results revealed that a considerable number of genes exhibit nonaccidental differential expression between the different tumor classes. Principal component analysis reflected the differences between the three tumor classes and their order of transition. Using a leave-one-out approach together with least squares support vector machines, we obtained an estimated classification test accuracy of 100% for the distinction between stage I and advanced-stage disease and 76.92% for the distinction between platin-resistant versus platin-sensitive disease in FIGO stage III/IV. These results indicate that gene expression patterns could be useful in clinical management of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16515583     DOI: 10.1111/j.1525-1438.2006.00321.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (USP17) Gene Family, is a Potential Target for Epithelial-Mesenchymal Transition in High-Grade Serous Ovarian Cancer.

Authors:  Nuri Yildirim; Gizem Calibasi Kocal; Zerrin Isik; Bahadır Saatli; Ugur Saygili; Tugba Uysal; Cagnur Ulukus; Meral Koyuncuoglu; Hulya Ellidokuz; Yasemin Basbinar
Journal:  Reprod Sci       Date:  2018-09-09       Impact factor: 3.060

2.  Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

Authors:  Stefan Bentink; Benjamin Haibe-Kains; Thomas Risch; Jian-Bing Fan; Michelle S Hirsch; Kristina Holton; Renee Rubio; Craig April; Jing Chen; Eliza Wickham-Garcia; Joyce Liu; Aedin Culhane; Ronny Drapkin; John Quackenbush; Ursula A Matulonis
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

Review 3.  Prediction of resistance to chemotherapy in ovarian cancer: a systematic review.

Authors:  Katherine L Lloyd; Ian A Cree; Richard S Savage
Journal:  BMC Cancer       Date:  2015-03-11       Impact factor: 4.430

4.  Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation.

Authors:  Olivier Gevaert; Frank De Smet; Toon Van Gorp; Nathalie Pochet; Kristof Engelen; Frederic Amant; Bart De Moor; Dirk Timmerman; Ignace Vergote
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

5.  An integrative model for recurrence in ovarian cancer.

Authors:  Alexandros Laios; Sharon A O'Toole; Richard Flavin; Cara Martin; Martina Ring; Noreen Gleeson; Tom D'Arcy; Eamonn P J McGuinness; Orla Sheils; Brian L Sheppard; John J O' Leary
Journal:  Mol Cancer       Date:  2008-01-22       Impact factor: 27.401

6.  Signature Evaluation Tool (SET): a Java-based tool to evaluate and visualize the sample discrimination abilities of gene expression signatures.

Authors:  Chih-Hung Jen; Tsun-Po Yang; Chien-Yi Tung; Shu-Han Su; Chi-Hung Lin; Ming-Ta Hsu; Hsei-Wei Wang
Journal:  BMC Bioinformatics       Date:  2008-01-28       Impact factor: 3.169

7.  Identifying a miRNA signature for predicting the stage of breast cancer.

Authors:  Srinivasulu Yerukala Sathipati; Shinn-Ying Ho
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.